The estimated Net Worth of Robert Kramer is at least $9.75 millió dollars as of 8 February 2021. Mr. Kramer owns over 45,397 units of Emergent Biosolutions Inc stock worth over $1,152,230 and over the last 18 years he sold EBS stock worth over $4,900,433. In addition, he makes $3,693,820 as President, Chief Executive Officer és Director at Emergent Biosolutions Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Kramer EBS stock SEC Form 4 insiders trading
Robert has made over 9 trades of the Emergent Biosolutions Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 45,397 units of EBS stock worth $1,397,774 on 8 February 2021.
The largest trade he's ever made was selling 50,189 units of Emergent Biosolutions Inc stock on 15 April 2014 worth over $1,221,600. On average, Robert trades about 4,664 units every 56 days since 2006. As of 8 February 2021 he still owns at least 152,210 units of Emergent Biosolutions Inc stock.
You can see the complete history of Mr. Kramer stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Kramer biography
Robert G. Kramer Sr., is re designated as President, Chief Executive Officer, Director of the Company since April 2019. He served as our president and chief operating officer from March 2018 to March 2019. Previously, he also served as our executive vice president, administration, chief financial officer and treasurer from September 2012 until his promotion to president and chief operating officer in March 2018. Mr. Kramer first joined us in 1999 as our chief financial officer. From 1999 until his prior retirement in 2010, he held various executive positions with the last being president of Emergent Biodefense Operations Lansing. Mr. Kramer returned to the company in 2011 as the interim head of the biosciences division, and then as interim executive vice president, corporate services division. Prior to joining us in 1999, Mr. Kramer held various financial management positions at Pharmaci Corporation, which subsequently merged with the Upjohn Company in 1995 and eventually became part of Pfizer Inc. Mr. Kramer holds an M.B.A. from Western Kentucky University and a B.S. in industrial management from Clemson University.
What is the salary of Robert Kramer?
As the President, Chief Executive Officer és Director of Emergent Biosolutions Inc, the total compensation of Robert Kramer at Emergent Biosolutions Inc is $3,693,820. There are no executives at Emergent Biosolutions Inc getting paid more.
How old is Robert Kramer?
Robert Kramer is 62, he's been the President, Chief Executive Officer és Director of Emergent Biosolutions Inc since 2019. There are 9 older and 11 younger executives at Emergent Biosolutions Inc. The oldest executive at Emergent Biosolutions Inc is Louis Sullivan, 86, who is the Independent Director.
What's Robert Kramer's mailing address?
Robert's mailing address filed with the SEC is 400 PROFESSIONAL DR, SUITE 400, , GAITHERSBURG, MD, 20879.
Insiders trading at Emergent Biosolutions Inc
Over the last 18 years, insiders at Emergent Biosolutions Inc have traded over $131,382,266 worth of Emergent Biosolutions Inc stock and bought 4,647 units worth $138,981 . The most active insiders traders include Seamus Mulligan, Fuad El Hibri és Shahzad Malik. On average, Emergent Biosolutions Inc executives and independent directors trade stock every 21 days with the average trade being worth of $147,206. The most recent stock trade was executed by Kathryn C Zoon on 4 June 2024, trading 10,000 units of EBS stock currently worth $61,100.
What does Emergent Biosolutions Inc do?
emergent biosolutions is a global life sciences company dedicated to one simple mission—to protect and enhance life. we develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. through our work, we envision protecting and enhancing 50 million lives with our products by 2025. additional information about the company may be found at www.emergentbiosolutions.com. follow us @emergentbiosolu and @life_at_emergent
What does Emergent Biosolutions Inc's logo look like?
Complete history of Mr. Kramer stock trades at Emergent Biosolutions Inc
Emergent Biosolutions Inc executives and stock owners
Emergent Biosolutions Inc executives and other stock owners filed with the SEC include:
-
Robert Kramer,
President, Chief Executive Officer, Director -
Fuad El-Hibri,
Executive Chairman of the Board -
Robert G. Kramer,
CEO, Pres & Exec. Director -
Richard Lindahl,
Chief Financial Officer, Executive Vice President, Treasurer -
Atul Saran,
Executive Vice President, Corporate Development, General Counsel and Corporate Secretary -
Adam Havey,
Executive Vice President - Business Operations -
Fuad El-Hibri,
Founder & Exec. Chairman -
Richard S. Lindahl,
Exec. VP, CFO & Treasurer -
Adam R. Havey,
Exec. VP & COO -
Atul Saran,
Exec. VP of Corp. Devel. & Ext. Affairs and Gen. Counsel -
Seamus Mulligan,
Director -
Ronald Richard,
Lead Independent Director -
Zsolt Harsanyi,
Independent Director -
Louis Sullivan,
Independent Director -
Jerome Hauer,
Independent Director -
George Joulwan,
Independent Director -
Kathryn Zoon,
Independent Director -
Sue Bailey,
Independent Director -
Marvin White,
Director -
Robert Burrows,
Vice President, Investor Relations -
Sean Kirk,
Executive Vice President, Manufacturing and Technical Operations -
Katherine Strei,
Executive Vice President, Human Resources and Communications, Chief Human Resources Officer -
Katherine Strei,
Exec. VP of HR & Chief HR Officer -
Nina DeLorenzo,
Sr. VP of Global Communications & Public Affairs -
Lynn Kieffer,
VP of Corp. Communications -
Howard Anderson,
Sr. VP & Chief Information Officer -
Karen L. Smith,
EVP, Chief Medical Officer -
John Niederhuber,
Director -
Daniel Abdun Nabi,
SVP Corp Aff, GC & Secretary -
L.L.C. Bio Pharm,,
10% owner -
Stephen Lockhart,
SVP Product Development -
L.L.C. Intervac,,
10% owner -
Steven Chatfield,
President, EPD UK & CSO -
R Don Elsey,
VP Finance, CFO & Treasurer -
Barry Labinger,
EVP, Biosciences Div. -
Denise Esposito,
SVP Legal Affairs & GC -
L.L.C. Biologika,,
-
Biologic Products, Inc. Mic...,
-
Kyle Keese,
SVP Mktg & Comm. -
Joe M Allbaugh,
Director -
Mauro Gibellini,
SVP Corporate Dev. -
Investments Ltd Microscience,
10% owner -
Shahzad Malik,
Director -
Edward Arcuri,
EVP & COO -
Thomas Zink,
SVP & CMO -
Robert Calvin Myers,
-
Joseph C Papa,
President and CEO -
Jennifer Lynne Fox,
EVP, Ext Aff, GC, Corp Sec -
Keith Katkin,
Director -
Coleen Glessner,
EVP, Quality & Ethics, and CPL -
Sujata Tyagi Dayal,
Director -
Paul Anthony Williams,
SVP, Products Business -
William Hartzel,
SVP, Bioservices -
Neal Franklin Fowler,
Director -
Donald W De Golyer,
Director